|
|
 |
|
Viewing report
|
|
|
|
The Cardiovascular Market Outlook to 2016
Business Insights, June 2011, Pages: 160
The large number of impending patent expirations of blockbuster drugs will negatively impact the cardiovascular pharmaceutical segment. Evolving strategies in this segment such as in-licensing of drug candidates, and marketing of authorized generics, along with the development of first-in-line novel therapeutics might offset the effects of genericization.
Features and benefits
- Gain an overview of the cardiovascular market, including analyses of the disease subcategories, market sizing, market forecasts, and growth drivers.
- Develop insights into the R&D pipeline of leading pharmaceutical companies, and compare the prospects for individual pipeline drugs.
- Assess the innovative first-in-class drugs in the various therapeutic subcategories, and judge their future market potential.
- Review the marketed product portfolio of the key players in this segment, and gain insights into the strategies that fuel their growth.
- Examine the epidemiology of major cardiovascular indications, and assess the major risk factors and prevalence forecasts to 2016.
Highlights
- Cardiovascular diseases encompass a range of ailments such as hypertension, dyslipidemia, stroke, atherosclerosis, thrombosis, and coronary artery disease.
- Dyslipidemia was the indication with the highest reported prevalence in 2010 with an estimated 336 million cases in the seven major markets.
- Antidyslipidemic drugs occupied 18% of the cardiovascular segment in 2010. The entry of Lipitor generics in 2011 is expected to negatively impact future prospects of sales in this segment. Dalcetrapib, a CETP inhibitor, manufactured by Roche, is a potential blockbuster in this segment that could offset the negative impact of genericization.
- Antithrombotics recorded strong sales in 2010, and occupied a market share of 11%. This segment is forecast to deliver strong growth in the next two years owing to the commercialization of recently approved products such as Pradaxa and Xarelto and the expected launch of Pfizer/BMS’s apixaban in the US.
Your key questions answered
- What are the key growth drivers and resistors that will affect various therapeutic sub-categories of the cardiovascular market?
- What are the novel therapeutics being developed in the cardiovascular segment, and which of these offer significant potential for future growth?
- What are the various R&D strategies of top pharmaceutical companies, and how do these strategies help in cost containment and sustenance of growth?
- What are the key brands in the various therapeutic subcategories, and which of these are likely to enjoy significant growth in future?
- How have the leading players built a strong position in the cardiovascular segment and what are their growth strategies?
|
|
|
|
